BRIEF published on 04/10/2025 at 19:05, 7 months 24 days ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 7 months 24 days ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 9 months 15 days ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 9 months 15 days ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 10 months 6 days ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 10 months 6 days ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 11 months 12 days ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
